StockDuty ← Dashboard Sep 04, 2026 09:18 PM ET
CatalystFDA/Bio

IONIS PHARMACEUTICALS FALLS AFTER PELACARSEN FAILS KEY PHASE 3 HEART TRIAL - SEEKINGALPHA

Phase 3 failure triggers clinical and regulatory setback for IONIS.

What changed
Phase 3 failure triggers clinical and regulatory setback for IONIS.
Why it matters
Phase 3 failure triggers clinical and regulatory setback for IONIS. — impact context not separately stored; see What changed.
Sources
seekingalpha
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →